DEF: Revolution Medicines Sets Date for 2025 Annual Stockholders Meeting
Proxy Statement
Revolution Medicines will hold its 2025 Annual Meeting of Stockholders online on June 26, 2025, to vote on director elections, auditor ratification, and executive compensation.
Summary
- Revolution Medicines, Inc. will hold its 2025 Annual Meeting of Stockholders on June 26, 2025, at 7:30 a.m. Pacific Time, entirely online.
- Stockholders of record as of April 28, 2025, are eligible to vote.
- The meeting will address the election of four Class II directors, ratification of PricewaterhouseCoopers LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
- The Board of Directors recommends voting FOR the election of director nominees, FOR the ratification of PricewaterhouseCoopers LLP, and FOR the approval of the Say-on-Pay proposal.
- Stockholders can vote online, by phone, or by mail.
- The company had 186,261,742 shares of common stock outstanding as of the record date, excluding 2,173,917 shares issuable upon exercise of pre-funded warrants.
- A quorum requires a majority in voting power of the shares of common stock issued and outstanding and entitled to vote.
Sentiment
Score: 7
Explanation: The document is neutral in tone, primarily providing logistical information about the upcoming annual meeting. The board's recommendations to vote FOR all proposals suggest a positive outlook, but the document itself is not overtly positive or negative.
Positives
- The Board recommends voting FOR all proposals, indicating confidence in the company's direction.
- The company provides multiple convenient methods for stockholders to vote.
Future Outlook
The company intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for its 2026 annual meeting of stockholders.
Management Comments
- On behalf of the Board of Directors, I would like to express our appreciation for your interest in Revolution Medicines, said Mark A. Goldsmith, M.D., Ph.D., Chair of the Board, Chief Executive Officer and President.
Stakeholder Impact
- Shareholders are asked to vote on key company matters.
- The outcome of the votes will influence the company's governance and direction.
Next Steps
- Stockholders are encouraged to vote via the Internet, phone, or mail.
- Stockholders can attend the virtual Annual Meeting on June 26, 2025.
Key Dates
| Date | Description |
|---|---|
| 2014-11-01 | Alexis Borisy has served on our Board of Directors since November 2014. |
| 2015-03-01 | Elizabeth McKee Anderson has served on our Board of Directors since March 2015. |
| 2017-03-01 | Barbara Weber, M.D. has served on our Board of Directors since March 2017. |
| 2018-03-01 | Thilo Schroeder, Ph.D. has served on our Board of Directors since March 2018. |
| 2021-06-01 | Flavia Borellini, Ph.D. has served on our Board of Directors since June 2021. |
| 2022-06-01 | Sushil Patel, Ph.D. has served on our Board of Directors since June 2022. |
| 2022-07-01 | Lorence Kim, M.D. has served on our Board of Directors since July 2022. |
| 2023-11-01 | Sandra J. Horning, M.D . has served on our Board of Directors since November 2023. |
| 2024-08-01 | Frank K. Clyburn, Jr. has served on our Board of Directors since August 2024. |
| 2025-04-28 | Record Date for voting at the Annual Meeting. |
| 2025-04-29 | Date of the notice of the Annual Meeting. |
| 2025-05-16 | Proxy materials will be first made available on or about this date. |
| 2025-06-26 | Date of the Annual Meeting of Stockholders. |
| 2025-12-30 | Deadline for stockholder proposals to be included in next year's proxy materials. |
| 2026-02-26 | Start of the window for stockholders to present a proposal for next year's annual meeting. |
| 2026-03-28 | End of the window for stockholders to present a proposal for next year's annual meeting. |
| 2026-04-27 | Deadline for stockholders intending to solicit proxies in support of director nominees to provide notice. |
Keywords
Annual Meeting, Stockholders, Proxy Statement, Director Election, Executive Compensation, PricewaterhouseCoopers, Audit Committee, Revolution Medicines, Voting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.